Recognise products approved in GHTF countries, says NZ industry - Update
This article was originally published in SRA
Executive Summary
The New Zealand medtech industry association, the MTANZ, has called for the introduction of a regulatory system that would involve the unilateral recognition of medical devices that have been approved for marketing in at least one of the five founding members of the Global Harmonization Task Force (ie the US, European Union, Japan, Canada and Australia)1.
You may also be interested in...
EU Accelerated Assessment Tracker
Marinus’s ganaxolone has lost its accelerated assessment status mid-review at the European Medicines Agency while Roche’s glofitamab will be fast-tracked once a filing has been made.
EU Accelerated Assessment Tracker
The EU filing for AstraZeneca’s nirsevimab is being reviewed under the accelerated pathway at the European Medicines Agency. Also, Janssen should know by now whether its planned filing for Zejula plus Zytiga will get the same treatment – as should SIFI for its planned Akantior filing.
AZ Secures EU Fast-Tack Review For Nirsevimab
There could be a regulatory decision on AstraZeneca and Sanofi's nirsevimab in the EU in H2 as a result of the European Medicines Agency speeding up its review of the marketing application for the potential new immunization against RSV in all infants.